207_Combined course Presentations

DAHANCA19: RT/CRT ± EGFR-I

619 randomized patients

310 patients zalutumumab

309 patients control

9 not eligible: 8 regret participation 1 died before start

2 not eligible: 1 regret participation 1 distant disease

70 ART+ Zalu 21 HF-ART 210 C-ART+Zalu

74 ART 21 HF-ART 212 C-ART

71 locoreg. failures 48 dead of disease

63 locoreg. failures 42 dead of disease

301 patients in final analysis

307 patients in final analysis

Eriksen 2015